Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo, Andrea Dell'Amore, Elena Scagliori, Mariaenrica Tinè, Fiorella Calabrese, Gaetano Benati, Matteo Sepulcri, Cristina Baiocchi, Michele Milella, Federico Rea, Valentina Guarneri
Lung cancer (LC) is the leading cause of cancer-related death worldwide, mostly because the lack of a screening program so far. Although smoking cessation has a central role in LC primary prevention, several trials on LC screening through low-dose computed tomography (LDCT) in a high risk population showed a significant reduction of LC related mortality. Most trials showed heterogeneity in terms of selection criteria, comparator arm, detection nodule method, timing and intervals of screening and duration of the follow-up...
March 17, 2023: Cancer Treatment Reviews
#2
REVIEW
Anne Petzold, Theresa Steeb, Anja Wessely, Elias A T Koch, Julio Vera, Carola Berking, Markus V Heppt
BACKGROUND: Distinct systemic treatments exist for metastatic uveal melanoma. Tebentafusp and combined immune checkpoint blockade (ICB) with ipilimumab plus anti-PD-1 antibodies are the most commonly used treatment options but their comparative efficacy is unclear. The aim of this study is to compare currently available systemic treatments regarding overall survival (OS) and progression-free survival (PFS) with a focus on the comparison of tebentafusp versus combined ICB. METHODS: The protocol for this study was defined a priori and registered online in the PROSPERO international prospective register of systematic reviews (CRD42022308356, date of registration: 7...
March 13, 2023: Cancer Treatment Reviews
#3
REVIEW
Erika Martinelli, Dirk Arnold, Andres Cervantes, Sebastian Stintzing, Eric Van Cutsem, Josep Tabernero, Julien Taieb, Harpreet Wasan, Fortunato Ciardiello
Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8-12% of patients and is characterised by an aggressive clinical course and poor prognosis. Here we review the current knowledge on BRAFV600E -mutant mCRC and provide a series of consensus statements on its clinical management. The treatment landscape for BRAFV600E -mutant mCRC has changed greatly due to the emergence of molecular targeted therapies (including BRAF inhibitors) and immune checkpoint inhibitors...
March 11, 2023: Cancer Treatment Reviews
#4
REVIEW
Yakup Ergun, Gokhan Ucar, Baran Akagunduz
BACKGROUND: The prognostic differences between HER2-zero and HER2-low breast cancer (BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between HER2-low and HER2-zero in terms of clinicopathological factors and survival outcomes in early-stage BC. METHODS: We searched major databases and congress proceedings until November 1, 2022 to identify studies comparing HER2-zero and HER2-low in early-stage BC. HER2-zero immunohistochemically (IHC) was defined as score 0, while HER2-low was defined as IHC 1+ or 2+/in situ hybridization negative...
March 6, 2023: Cancer Treatment Reviews
#5
REVIEW
Tim Schutte, Alaa Embaby, Neeltje Steeghs, Stevie van der Mierden, Willemien van Driel, Martin Rijlaarsdam, Alwin Huitema, Frans Opdam
INTRODUCTION: The anti-tumor activity of WEE1 inhibitors (WEE1i) in gynecological malignancies has recently been demonstrated in clinical trials and its rationale is based on biological/molecular features of gynecological cancers. With this systematic review, we aim to outline the clinical development and current evidence regarding the efficacy and safety of these targeted agents in in this patient group. METHODS: Systematic literature review of trials including patients with gynecological cancers treated with a WEE1i...
March 3, 2023: Cancer Treatment Reviews
#6
REVIEW
Jason K Wong, Howard J Lim, Vincent C Tam, Kelly W Burak, Laura A Dawson, Prosanto Chaudhury, Robert J Abraham, Brandon M Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maja Segedi, David M Liu
BACKGROUND: Hepatocellular carcinoma (HCC) a leading cause of cancer mortality worldwide and approximately one-third of patients present with intermediate-stage disease. The treatment landscape of intermediate-stage HCC is rapidly evolving due to developments in local, locoregional and systemic therapies. Treatment recommendations focused on this heterogenous disease stage and that take into account the Canadian reality are lacking. To address this gap, a pan-Canadian group of experts in hepatology, transplant, surgery, radiation therapy, nuclear medicine, interventional radiology, and medical oncology came together to develop consensus recommendations on management of intermediate-stage HCC relevant to the Canadian context...
March 2, 2023: Cancer Treatment Reviews
#7
REVIEW
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Triple-positive breast tumors overexpress human epidermal growth factor receptor 2 (HER2) and are positive for hormone receptor (HR) expression. Data from real-life and clinical trials show that estrogen receptor (ER) expression affects the response to combinations of anti-HER2 and associated systemic therapies. Despite triple-positive tumors having decreased response rates compared to HR-negative/HER2-positive breast cancers, optimizing anti-HER2 treatment with dual anti-HER2 blockade remains important for optimal disease control...
February 28, 2023: Cancer Treatment Reviews
#8
REVIEW
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, Alberto Servetto, Stefania Belli, Antonio Santaniello, Sarah Scagliarini, Felice Crocetto, Roberto Bianco, Luigi Formisano
Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2% of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors (FGFRs) have recently emerged as a novel therapeutic target in cancer. In particular, FGFR3 genomic alterations are potent oncogenic drivers in bladder cancer and represent predictive biomarkers of response to FGFR inhibitors. Indeed, overall ∼50% of bladder cancers have somatic mutations in the FGFR3 -coding sequence (Cappellen et al...
February 28, 2023: Cancer Treatment Reviews
#9
REVIEW
Chiara Ciccarese, Alessandro Strusi, Daniela Arduini, Pierluigi Russo, Giuseppe Palermo, Nazario Foschi, Marco Racioppi, Giampaolo Tortora, Roberto Iacovelli
Standard treatment for localized non-metastatic renal cell carcinoma (RCC) is radical or partial nephrectomy. However, after radical surgery, patients with stage II-III have a substantial risk of relapse (around 35%). To date a unique standardized classification for the risk of disease recurrence still lack. Moreover, in the last years great attention has been focused in developing systemic therapies with the aim of improving the disease-free survival (DFS) of high-risk patients, with negative results from adjuvant VEGFR-TKIs...
February 24, 2023: Cancer Treatment Reviews
#10
REVIEW
Volkmar Müller, Rupert Bartsch, Nancy U Lin, Filippo Montemurro, Mark D Pegram, Sara M Tolaney
BACKGROUND: There is an increasing need for developing effective therapies for managing intracranial disease in patients with human epidermal growth factor receptor 2-positive (HER2 +) metastatic breast cancer and brain metastases (BM), as this population is growing and has historically been excluded from large clinical trials. In this systematic literature review, we aimed to provide a comprehensive overview of the epidemiology, unmet needs, and global treatment landscape for patients with HER2 + metastatic breast cancer and BM, with a particular focus on heterogeneity across clinical trial designs in this setting...
February 23, 2023: Cancer Treatment Reviews
#11
REVIEW
Alfredo Berruti, Sergio Bracarda, Orazio Caffo, Enrico Cortesi, Rolando D'Angelillo, Marzia Del Re, Gaetano Facchini, Giovanni Pappagallo, Giuseppe Procopio, Roberto Sabbatini, Daniele Santini
Non-metastatic castration resistant prostate cancer (nmCRPC) is a clinical setting defined as confirmed rising levels of PSA in patients treated with ADT but without detectable metastases on conventional imaging with computerized tomography (CT) and technetium-99 m scintigraphy. Men with nmCRPC and a PSA doubling time (PSADT) ≤ 10 months are considered at high risk of rapidly developing metastases with a consequent possible impact on survival. Three recent phase III trials have demonstrated, in this setting, the efficacy of adding a next-generation androgen receptor targeted agent (ARTA) to ADT in respect to ADT only, in delaying the development of metastases (metastasis-free survival, MFS) and prolong overall survival...
February 14, 2023: Cancer Treatment Reviews
#12
J Y Blay, N Hindi, J Bollard, S Aguiar, M Angel, B Araya, R Badilla, D Bernabeu, F Campos, C H S Caro-Sánchez, B Carvajal, A Carvajal Montoya, S Casavilca-Zambrano, V Castro-Oliden, M Chacón, M Clara, P Collini, R Correa Genoroso, F D Costa, M Cuellar, A P Dei Tos, H R Dominguez Malagon, D Donati, A Dufresne, M Eriksson, M Farias-Loza, P Fernandez, A M Frezza, T Frisoni, D Y Garcia-Ortega, H Gelderblom, F Gouin, M C Gómez-Mateo, A Gronchi, J Haro, L Huanca, N Jimenez, M Karanian, B Kasper, B B Lopes David, A Lopez-Pousa, G Lutter, H Martinez-Said, J Martinez-Tlahuel, C A Mello, J M Morales Pérez, S Moura David, A G Nascimento, E J Ortiz-Cruz, E Palmerini, S Patel, Y Pfluger, S Provenzano, A Righi, A Rodriguez, R Salas, T T G Santos, K Scotlandi, T Soule, S Stacchiotti, C Valverde, F Waisberg, E Zamora Estrada, J Martin-Broto
No abstract text is available yet for this article.
February 14, 2023: Cancer Treatment Reviews
#13
REVIEW
Jeremie Calais, Stephen M Eulau, Linda Gardner, Ralph J Hauke, Ayse T Kendi, Neal D Shore, Song Zhao
Prostate cancer (PC) is the second most commonly diagnosed cancer in the United States. Advanced PC evolves to metastatic castration-resistant PC (mCRPC). Theranostics combining prostate-specific membrane antigen-targeted positron emission tomography imaging and radioligand therapy (RLT) represents a precision medicine approach to PC treatment. With the recent approval of lutetium Lu 177 (177 Lu) vipivotide tetraxetan for men with mCRPC, the utilization of RLT will increase. In this review, we suggest a framework for incorporating RLT for PC into clinical practice...
February 11, 2023: Cancer Treatment Reviews
#14
REVIEW
Eva Blondeaux, Luca Arecco, Kevin Punie, Rossella Graffeo, Angela Toss, Carmine De Angelis, Lucia Trevisan, Giulia Buzzatti, Sabine C Linn, Peter Dubsky, Mara Cruellas, Ann H Partridge, Judith Balmaña, Shani Paluch-Shimon, Matteo Lambertini
Approximately 10% of breast cancers are associated with the inheritance of a pathogenic variant (PV) in one of the breast cancer susceptibility genes. Multiple breast cancer predisposing genes, including TP53, are responsible for the increased breast cancer risk. Tumor protein-53 (TP53) germline PVs are associated with Li-Fraumeni syndrome, a rare autosomal dominant inherited cancer predisposition syndrome associated with early-onset pediatric and multiple primary cancers such as soft tissue and bone sarcomas, breast cancer, brain tumors, adrenocortical carcinomas and leukemias...
January 31, 2023: Cancer Treatment Reviews
#15
REVIEW
Ying Yu, Yehao Yang, Hui Li, Yun Fan
In non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) alterations, chemotherapy remains the standard treatment over a decade, due to the minor efficacy of traditional pan-HER tyrosine kinase inhibitors (TKIs) and HER2-targeted monoclonal antibodies. In recent years, novel selective HER2 TKIs have been developed for pretreated HER2-mutant patients. In particular, pyrotinib has shown moderate efficacy as well as a manageable safety profile, and it is now being further evaluated as monotherapy or combined with other existing therapies; by contrast, while poziotinib has demonstrated promising preliminary results, the high rates of toxicity has hampered subsequent studies...
January 27, 2023: Cancer Treatment Reviews
#16
REVIEW
Bishal Gyawali, Meghan Bowman, Isobel Sharpe, Matthew Jalink, Siddhartha Srivastava, Don Thiwanka Wijeratne
Breast cancer places a substantial burden on patient physical and mental wellbeing, and the delivery of high-quality supportive care is essential at all stages of the disease. Given the increased uptake of technology in recent years, eHealth interventions may be a convenient and accessible method for supportive care. Within this context, we conducted a systematic review to describe and quantify the use of eHealth for breast cancer supportive care. We searched MEDLINE, EMBASE, and CINAHL databases for primary research studies published from 2016 to 2021 (present) that assessed the effects of eHealth interventions on adult patients with breast cancer...
January 27, 2023: Cancer Treatment Reviews
#17
REVIEW
Bartłomiej Tomasik, Michał Bieńkowski, Zuzanna Górska, Klaudia Gutowska, Paulina Kumięga, Jacek Jassem, Renata Duchnowska
Brain metastases (BM) are a common and devastating manifestation of breast cancer (BC). BM are particularly frequent in the HER2-positive and triple-negative breast cancer phenotypes and usually occur following the metastatic spread to extracranial sites. Several genes mediating BM and biomarkers predicting their risk in BC have been reported in the past decade. These findings have advanced the understanding of BM pathobiology and paved the way for developing new therapeutic strategies but they still warrant a thorough clinical validation...
January 27, 2023: Cancer Treatment Reviews
#18
REVIEW
Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagnì, Valeria Altamura, Giovanni Scambia, Gennaro Daniele
BACKGROUND: Several regimens have been introduced in clinical practice in the last twenty years to treat chemotherapy-induced nausea and vomiting (CINV). However, direct comparative data remain insufficient, as many new regimes lack head-to-head comparisons. In this study, through an indirect comparison, we overcome this limit by providing the most up-to-date estimate of the efficacy and safety of all combinations used for HEC-induced nausea and vomiting. PATIENTS AND METHODS: We retrieved randomized controlled trials (RCTs) published in Pubmed, Embase, and Cochrane Library until June, 30th 2022...
January 21, 2023: Cancer Treatment Reviews
#19
REVIEW
F Miglietta, A Fabi, D Generali, M V Dieci, G Arpino, G Bianchini, S Cinieri, P F Conte, G Curigliano, M De Laurentis, L Del Mastro, S De Placido, A Gennari, F Puglisi, A Zambelli, F Perrone, V Guarneri
Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC...
March 2023: Cancer Treatment Reviews
#20
REVIEW
Farshid Dayyani, Teresa Macarulla, Andrew Johnson, Zev A Wainberg
INTRODUCTION: The aim of this review was to characterize the second- and later-line (≥2L) treatment landscape for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: This systematic literature review (PROSPERO: CRD42021279753) involved searches of MEDLINE® and Embase to identify results from prospective studies of ≥2L treatment options for metastatic pancreatic cancer published from 2016 to 2021. Publications were screened according to predetermined eligibility criteria; population-level data were extracted using standardized data fields...
February 2023: Cancer Treatment Reviews
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
